Naphthols useful in antiviral methods

US6140368A · kind A · utility

Assignees

• The Regents of the University of California · US
• Rutgers, The University of New Jersey · US

Inventors

• George L. Kenyon · San Francisco, US
• Margaret Stauber · Germantown, US
• Karl Maurer · Ross, US
• Dolan Eargle · San Francisco, US
• Angelika Muscate · Soest, DE
• Andrew Leavitt · San Francisco, US
• Diana C. Roe · Newark, US
• Todd Ewing · San Diego, US
• Allan G. Skillman, Jr. · San Francisco, US
• Edward Arnold · Montgomery, US
• Irwin D. Kuntz · Greenbrae, US
• Malin Young · Livermore, US

Key dates

• Filing date: May 4, 1998
• Grant date: Oct 31, 2000
• Expiry date: May 4, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C09B33/056
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.